Disclaimer and Forward-looking statements

Disclaimer

This document is the sole responsibility of the directors Futura Medical plc (the "Company"). N+1 Singer Advisory LLP ("N+1 Singer"), which is authorised and regulated by the Financial Conduct Authority, is acting as nominated adviser and broker to the Company. This document does not constitute a recommendation regarding the shares of the Company nor a representation that any dealing in those shares is appropriate. The Company accepts no duty of care whatsoever to the reader of this document in respect of its contents and the Company is not acting in any fiduciary capacity. The information contained in the document has not been verified, nor does this document purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in the Company. In all cases potential investors should conduct their own investigations and analysis concerning the risks associated with investing in shares in the Company, the business plans, the financial condition, assets and liabilities and business affairs of the Company, and the contents of this document.

This document (including its contents) is confidential and is for distribution in the United Kingdom only, to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 or any Order made thereunder, or to persons of a kind described in Articles 19 or 49 or 50 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) and, if permitted by applicable law, for distribution outside the United Kingdom to professions or institutions whose ordinary business involves them in engaging in investment activities. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

No offer or invitation or solicitation of any offer to acquire securities of the Company is being made now nor does this document constitute or form part of any invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000. No reliance may be placed for any purpose whatsoever on the information contained in this document or any assumptions made as to its completeness and no warranty or redocument is given by or on behalf of the Company nor its directors, employees, agents, N+1 Singer and advisors as to the accuracy or completeness of the information or opinions contained in this document and no liability is accepted by any of them for any such information or opinions, provided that nothing in this paragraph shall exclude liability for any redocument or warranty made fraudulently. The information and opinions contained in this document are provided as at the date hereof. This document is not, and should not be construed as, a recommendation or advice by the Company or its advisers to potential investors to participate in any investment in the Company.

The contents of this document are confidential and must not be copied, published, reproduced, distributed or passed in whole or in part to others at any time by recipients. This document is being provided to recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether oral or in writing, in connection with the Company.

This document may contain certain forward-looking statements. Whilst the directors believe all such statements to have been fairly made on reasonable assumptions, there can be no guarantee that any of them are accurate or that all relevant considerations have been included in the directors' assumptions; accordingly, no reliance whatsoever should be placed upon the accuracy of such statements, all of which are for illustrative purposes only, are based solely upon historic financial and other trends and information, including third party estimates, and may be subject to further verification. Neither the Company nor its directors, nor N+1 Singer (together with its associates) makes any redocument or warranty in respect of the accuracy, completeness or verification of the contents of the Document Materials. N+1 has not authorised or verified the contents of, or any part of, the document.

In particular, this document should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person or entity and, in particular, should not be distributed to United States residents, corporations, or other entities, US persons (as defined in Regulation S promulgated under the United States Securities Act of 1933 (as amended), persons with addresses in the United States of America (or any of its territories or possessions), Canada, Japan, the Republic of Ireland, the Republic of South Africa or Australia, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Notwithstanding the foregoing, the Company can distribute this document to US Persons (as defined above), persons with addresses in the United States of America (or its territories or possessions), United States residents, corporations or other entities if the Company is satisfied that an applicable exemption applies. Distribution of this document in the United States of America in the absence of such an applicable exemption may constitute a violation of United States securities law.

Forward looking statements

This document contains forward-looking statements. All statements contained herein that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the design of further clinical trials, the timing of the commencement of additional clinical trial(s) or regulatory processes and the availability of top-line data or updates on any such items, the importance of further clinical trial data to our development plans for MED2002, the potential of MED2002 as a topical gel for the treatment of erectile dysfunction, plans to enrol patients into clinical trials subject to appropriate approvals, and projected costs for alternate treatments for ED, and reference to or the use of third party market research data which has not been independently verified.

These forward-looking statements are based on management's current expectations, beliefs, estimates and projections about the Company's markets and assumptions relating to their development. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors including some which are beyond the Company's control and that may cause actual results, performance or achievements to be materially different from the expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history with current or prospective commercial partners; our ability to conclude commercial partnership deals on terms sufficiently attractive to generate returns to shareholder; our potential need for additional funding to complete development and commercialization of products if necessary or otherwise deemed appropriate, which funding may not be available and which may force us to delay, reduce or eliminate our development or commercialisation efforts; the reliance of our business on the success of out-licensed partners and our limited product portfolio for out-licensing, candidate under development; economic, political, regulatory and other risks involved with international commerce; the lengthy and expensive process of clinical product development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects which may arise in association with our products, and could adversely affect our ability to develop or commercialize them; potential delays in enrolling patients into trials, which could adversely affect our research and development efforts; we may not be successful in developing MED2002 in the manner intended; our ability to obtain approval for and commercialize MED2002 in multiple major pharmaceutical markets as a prescription or OTC product; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our "top-line" data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and out-licensing partners, and the risks related to these parties' ability to support the successful development and commercialisation of our products; and lawsuits related to patents covering our core technology or our products and the potential for our patents to be found invalid or unenforceable.

These and other important factors under the caption "Principal risks and uncertainties" in our Annual Report and Accounts for the financial year ended 31 December 2016 and in other shareholder communications, could cause actual results to differ materially from those indicated by the forward-looking statements made in this document. Any such forward-looking statements represent management's estimates as of the date of this document. The forward-looking statements made in this document relate only to events or beliefs as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this document except as required by law or by any appropriate regulatory authority.